Curr Opin Investig Drugs 2002 May;3(5):725-34 Books
Merck Research Laboratories, Department of Immunology, Rahway, NJ 07065, USA.
IDEC, in collaboration with Eisai, is developing IDEC-131 (E6040), a humanized monoclonal antibody (mAb) against CD154, the ligand for CD40 also called CD40L or gp39, for the potential treatment of several autoimmune diseases.
IDEC-131 is based on technology that IDEC licensed from Dartmouth Medical School where researchers demonstrated the biological effects of the anti-CD154 antibody in animal models of autoimmunity.
In January 2001, phase II trials in psoriasis and idiopathic thrombocytopenic purpura (ITP) were initiated.
By january 2002, a phase II trial in Crohn's disease was also ongoing.
A pilot, multicenter, multiple-dose phase I trial in moderate-to-severe psoriasis was initiated in January 2001.
This trial was ongoing in January 2002.
IDEC, in collaboration with Dartmouth Medical School had also initiated a phase I trial in multiple sclerosis by March 1999.
IDEC-131 was also previously being developed for systemic lupus ezythematosus (SLE), although no further development for this indication has been reported since the disclosure of disappointing phase II results in April 2000.
Analysts at Morgan Stanley predicted in February 2002, that the product would be launched in 2005, with sales of US $25 million, rising to US $75 million in 2006.